Table 4.

The estimated proportion of cured patients.

HR status	Clinical response	HER2 status	Histological grade	Number of lymph node metastases	Estimated proportion of cured patients
Negative	SD/PD	Negative	1 and 2	0	89.3%
				1 to 3	78.2%
				≥4	44.7%
			3	0	83.1%
				1 to 3	67.8%
				≥4	32.2%
		Positive	1 and 2	0	81.7%
				1 to 3	65.8%
				≥4	30.2%
			3	0	72.4%
				1 to 3	53.0%
				≥4	20.2%
	PR	Negative	1 and 2	0	87.3%
				1 to 3	74.6%
				≥4	39.8%
			3	0	80.1%
				1 to 3	63.4%
				≥4	28.0%
		Positive	1 and 2	0	78.6%
				1 to 3	61.2%
				≥4	26.2%
			3	0	68.3%
				1 to 3	48.1%
				≥4	17.2%
	CR	Negative	1 and 2	0	94.9%
				1 to 3	89.0%
				≥4	64.4%
			3	0	91.7%
				1 to 3	82.6%
				≥4	51.6%
		Positive	1 and 2	0	90.9%
				1 to 3	81.2%
				≥4	49.2%
			3	0	85.5%
				1 to 3	71.7%
				≥4	36.3%
Positive	SD/PD	Negative	1 and 2	0	71.2%
				1 to 3	51.5%
				≥4	19.3%
			3	0	59.2%
				1 to 3	38.4%
				≥4	12.3%
		Positive	1 and 2	0	57.0%
				1 to 3	36.3%
				≥4	11.3%
			3	0	43.8%
				1 to 3	25.1%
				≥4	7.0%
	PR	Negative	1 and 2	0	67.0%
				1 to 3	46.6%
				≥4	16.4%
			3	0	54.4%
				1 to 3	33.9%
				≥4	10.3%
		Positive	1 and 2	0	52.1%
				1 to 3	31.8%
				≥4	9.5%
			3	0	39.0%
				1 to 3	21.5%
				≥4	5.8%
	CR	Negative	1 and 2	0	84.7%
				1 to 3	70.5%
				≥4	34.9%
			3	0	76.5%
				1 to 3	58.4%
				≥4	24.0%
		Positive	1 and 2	0	74.8%
				1 to 3	56.1%
				≥4	22.3%
			3	0	63.6%
				1 to 3	42.9%
				≥4	14.4%